Bridgebio Pharma Inc (BBIO)

$47.69 +1.22 (2.63%)
Market Cap 8.82B
Revenue (ttm) 221.90M
Net Income (ttm) -535.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -241.44%
Debt to Equity Ratio -1.13
Volume 3,861,100
Avg Vol 3,106,794
Day's Range N/A - N/A
Shares Out 189.88M
Stochastic %K 86%
Beta 1.15
Analysts Strong Sell
Price Target $59.63

Company Profile

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 doub...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 391 9740
Address:
3160 Porter Drive, Suite 250, Palo Alto, United States
BIOTECH_GURU
BIOTECH_GURU Jul. 14 at 8:40 PM
$BBIO for those stating that I'm not patient. I have been very patient actually.
0 · Reply
DonCorleone77
DonCorleone77 Jul. 14 at 6:57 PM
$BBIO Information regarding Mizuho analyst note on BBIO issued today: https://x.com/CorleoneDon77/status/1944830995087098303 cc: @RonIsWrong
0 · Reply
Jblack500
Jblack500 Jul. 14 at 5:59 PM
$BBIO because Rome wasn't built in a day
0 · Reply
MikeyNJ
MikeyNJ Jul. 14 at 4:50 PM
$BBIO The stock is up because Attruby appears to be more effective with a better safety profile than Pfizer's Tafamidis. The TAM for ATTR-CM is currently estimated at 10-12 billion and projected to grow to 20 billion by 2030. Do the math. Tafamidis did 5.5 billion in 2024 sales. Analysts are now projecting 4+ billion in Attruby sales. They are now also starting to recognize the billion+ potential of the pipeline. The company is well capitalized with a current market cap of 9 billion. Big pharma is starving for revenue by M&A. BBIO seems like a pretty good place to look.
0 · Reply
astroplane
astroplane Jul. 14 at 4:25 PM
$BBIO I guess people are expecting an earnings blowout. I always wonder if the actuals can meet expectations on runups like this, even when the numbers are great. I got out at 46 on a small position and will watch closely (probably with regret). GL longs
0 · Reply
WAJeff
WAJeff Jul. 14 at 4:16 PM
$BBIO $48.66 52 week high
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Jul. 14 at 3:20 PM
$BBIO show me a better biotech and show me a better stock chart. You can't. $RKLB looking interesting . 50 might be achievable if markets go green. $ASTS always 💪. 100 by christmas. $MSTR lagging BTC. Room to run to 500. 🔥🔥🚀🚀🚀
1 · Reply
DonCorleone77
DonCorleone77 Jul. 14 at 3:04 PM
$BBIO Information regarding Citi analyst note on BBIO issued today: https://x.com/CorleoneDon77/status/1944774167628272060
0 · Reply
DonCorleone77
DonCorleone77 Jul. 14 at 3:03 PM
$BBIO Information regarding Scotiabank analyst report on BBIO issued Friday (7/11): https://x.com/CorleoneDon77/status/1944773263088914686
0 · Reply
DonCorleone77
DonCorleone77 Jul. 14 at 3:02 PM
$BBIO Information regarding Piper Sandler analyst report on BBIO issued yesterday: https://x.com/CorleoneDon77/status/1944771840041218346
0 · Reply
Latest News on BBIO
It is time for a move higher in biotech, says Mizuho's Jared Holz

Jul 7, 2025, 6:29 PM EDT - 7 days ago

It is time for a move higher in biotech, says Mizuho's Jared Holz

BMRN GILD INSM XBI

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

Jun 30, 2025, 7:30 AM EDT - 14 days ago

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

Jun 26, 2025, 7:30 AM EDT - 18 days ago

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

BridgeBio: New Data Bolsters The Bull Case

Jun 4, 2025, 3:34 AM EDT - 5 weeks ago

BridgeBio: New Data Bolsters The Bull Case

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 2, 2025, 7:30 AM EDT - 6 weeks ago

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

May 20, 2025, 7:30 AM EDT - 7 weeks ago

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

May 19, 2025, 12:33 PM EDT - 2 months ago

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 14, 2025, 4:01 PM EDT - 2 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

May 13, 2025, 7:30 AM EDT - 2 months ago

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

May 12, 2025, 7:30 AM EDT - 2 months ago

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025

May 7, 2025, 7:30 AM EDT - 2 months ago

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025

BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 9:43 PM EDT - 2 months ago

BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

Apr 29, 2025, 4:01 PM EDT - 2 months ago

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

Apr 28, 2025, 5:00 AM EDT - 2 months ago

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

BridgeBio: Early Signs Point To Blockbuster Revenues

Apr 22, 2025, 11:14 AM EDT - 2 months ago

BridgeBio: Early Signs Point To Blockbuster Revenues

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

Apr 22, 2025, 7:30 AM EDT - 2 months ago

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

Mar 31, 2025, 10:00 AM EDT - 3 months ago

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug

Mar 27, 2025, 3:20 PM EDT - 3 months ago

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug

AZN

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

Mar 27, 2025, 7:00 AM EDT - 3 months ago

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

Mar 24, 2025, 7:30 AM EDT - 4 months ago

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

BridgeBio Announces CFO Succession

Mar 17, 2025, 4:01 PM EDT - 4 months ago

BridgeBio Announces CFO Succession

BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

Feb 26, 2025, 2:49 AM EST - 4 months ago

BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

Feb 24, 2025, 4:09 PM EST - 5 months ago

BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

BridgeBio: Strong Start For Attruby

Feb 20, 2025, 1:34 PM EST - 5 months ago

BridgeBio: Strong Start For Attruby

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

Feb 20, 2025, 7:30 AM EST - 5 months ago

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025

Feb 13, 2025, 4:01 PM EST - 5 months ago

BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

Feb 11, 2025, 9:21 AM EST - 5 months ago

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

Top 4 Health Care Stocks You May Want To Dump In Q1

Jan 21, 2025, 6:06 AM EST - 6 months ago

Top 4 Health Care Stocks You May Want To Dump In Q1

BSX ISRG ITCI

BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval

Jan 15, 2025, 9:30 AM EST - 6 months ago

BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval

BridgeBio CEO Neil Kumar: Our heart disease drug staves off death and hospitalization

Jan 14, 2025, 3:40 PM EST - 6 months ago

BridgeBio CEO Neil Kumar: Our heart disease drug staves off death and hospitalization

BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

Jan 13, 2025, 11:00 AM EST - 6 months ago

BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

Jan 8, 2025, 11:13 AM EST - 6 months ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BMY IOVA LLY MDGL MRK PFE

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

Jan 8, 2025, 7:30 AM EST - 6 months ago

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Dec 13, 2024, 7:18 AM EST - 7 months ago

Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology

Dec 3, 2024, 8:00 AM EST - 7 months ago

Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market

Nov 25, 2024, 9:03 AM EST - 8 months ago

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market

PFE

BridgeBio: Next Chapter Begins After Attruby Approval

Nov 24, 2024, 3:48 PM EST - 8 months ago

BridgeBio: Next Chapter Begins After Attruby Approval

US FDA approves BridgeBio's drug for rare heart condition

Nov 22, 2024, 7:25 PM EST - 8 months ago

US FDA approves BridgeBio's drug for rare heart condition

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

Nov 22, 2024, 7:11 PM EST - 8 months ago

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

Nov 19, 2024, 2:44 PM EST - 8 months ago

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

Nov 18, 2024, 11:15 AM EST - 8 months ago

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director

Nov 18, 2024, 8:00 AM EST - 8 months ago

BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

Nov 18, 2024, 5:30 AM EST - 8 months ago

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With Caveats

Nov 14, 2024, 10:41 AM EST - 8 months ago

BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With Caveats

BridgeBio Announces Publication of Case Study Exploring Portfolio Theory's Impact on Biomedical Innovation in The Journal of Portfolio Management

Nov 5, 2024, 7:30 AM EST - 8 months ago

BridgeBio Announces Publication of Case Study Exploring Portfolio Theory's Impact on Biomedical Innovation in The Journal of Portfolio Management

BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker, in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors

Oct 30, 2024, 8:00 AM EDT - 9 months ago

BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker, in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors

BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024

Oct 24, 2024, 7:30 AM EDT - 9 months ago

BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024

BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions

Oct 3, 2024, 7:30 AM EDT - 10 months ago

BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions

BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease

Sep 30, 2024, 1:17 PM EDT - 10 months ago

BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease

BIOTECH_GURU
BIOTECH_GURU Jul. 14 at 8:40 PM
$BBIO for those stating that I'm not patient. I have been very patient actually.
0 · Reply
DonCorleone77
DonCorleone77 Jul. 14 at 6:57 PM
$BBIO Information regarding Mizuho analyst note on BBIO issued today: https://x.com/CorleoneDon77/status/1944830995087098303 cc: @RonIsWrong
0 · Reply
Jblack500
Jblack500 Jul. 14 at 5:59 PM
$BBIO because Rome wasn't built in a day
0 · Reply
MikeyNJ
MikeyNJ Jul. 14 at 4:50 PM
$BBIO The stock is up because Attruby appears to be more effective with a better safety profile than Pfizer's Tafamidis. The TAM for ATTR-CM is currently estimated at 10-12 billion and projected to grow to 20 billion by 2030. Do the math. Tafamidis did 5.5 billion in 2024 sales. Analysts are now projecting 4+ billion in Attruby sales. They are now also starting to recognize the billion+ potential of the pipeline. The company is well capitalized with a current market cap of 9 billion. Big pharma is starving for revenue by M&A. BBIO seems like a pretty good place to look.
0 · Reply
astroplane
astroplane Jul. 14 at 4:25 PM
$BBIO I guess people are expecting an earnings blowout. I always wonder if the actuals can meet expectations on runups like this, even when the numbers are great. I got out at 46 on a small position and will watch closely (probably with regret). GL longs
0 · Reply
WAJeff
WAJeff Jul. 14 at 4:16 PM
$BBIO $48.66 52 week high
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Jul. 14 at 3:20 PM
$BBIO show me a better biotech and show me a better stock chart. You can't. $RKLB looking interesting . 50 might be achievable if markets go green. $ASTS always 💪. 100 by christmas. $MSTR lagging BTC. Room to run to 500. 🔥🔥🚀🚀🚀
1 · Reply
DonCorleone77
DonCorleone77 Jul. 14 at 3:04 PM
$BBIO Information regarding Citi analyst note on BBIO issued today: https://x.com/CorleoneDon77/status/1944774167628272060
0 · Reply
DonCorleone77
DonCorleone77 Jul. 14 at 3:03 PM
$BBIO Information regarding Scotiabank analyst report on BBIO issued Friday (7/11): https://x.com/CorleoneDon77/status/1944773263088914686
0 · Reply
DonCorleone77
DonCorleone77 Jul. 14 at 3:02 PM
$BBIO Information regarding Piper Sandler analyst report on BBIO issued yesterday: https://x.com/CorleoneDon77/status/1944771840041218346
0 · Reply
Papermoon347
Papermoon347 Jul. 14 at 2:56 PM
$BBIO Incredible run from the doldrums and seems not done yet
0 · Reply
CH_Expat
CH_Expat Jul. 14 at 2:51 PM
$BBIO Thanks to a degenerated IQ65 football star, dwarfism made it to world mainstream media for once.
0 · Reply
RonIsWrong
RonIsWrong Jul. 14 at 2:33 PM
$BBIO new highs again.
1 · Reply
Jblack500
Jblack500 Jul. 14 at 2:25 PM
$BBIO $EXEL $GILD $SMMT "Moving on up to the east side. I finally got a piece of the pie.
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Jul. 14 at 1:34 PM
$BBIO $PFE $ALNY how does 4B in sales = $70 ? Their have a very good pipeline. These analysts are trash.
1 · Reply
DonCorleone77
DonCorleone77 Jul. 14 at 1:18 PM
$BBIO Leerink raises BridgeBio price target raised to $56 from $53 cc: @RonIsWrong
0 · Reply
JarvisFlow
JarvisFlow Jul. 14 at 1:01 PM
Piper Sandler has updated their rating for BridgeBio Pharma ( $BBIO ) to Overweight with a price target of 68.
0 · Reply
DonCorleone77
DonCorleone77 Jul. 14 at 1:00 PM
$BBIO Information regarding Wells Fargo analyst report on BBIO issued Friday (7/11): https://x.com/CorleoneDon77/status/1944743686568329613 cc: @RonIsWrong
0 · Reply
G101SPM
G101SPM Jul. 14 at 11:53 AM
$BBIO $46.60 bid. *DAC (dollar average cost includes partial SELL to reduce net cost to $27.91. EXIT $55.00. BRIEF: BridgeBio (BBIO) initiated with a Buy at Jefferie. * Click SEARCH (magnifying glass) icon on our landing page to review the postings.
0 · Reply
DonCorleone77
DonCorleone77 Jul. 14 at 11:30 AM
$BBIO Piper Sandler raised their price target on BridgeBio to $68 from $63 - Keeps 'Overweight' rating
1 · Reply
JarvisFlow
JarvisFlow Jul. 14 at 11:30 AM
Jefferies has adjusted their stance on BridgeBio Pharma ( $BBIO ), setting the rating to Buy with a target price of 70.
0 · Reply
Quantumup
Quantumup Jul. 14 at 10:26 AM
Jefferies🏁 $BBIO Buy-$70 and said, "We believe Attruby (oral TTR stabilizer) could become a $4B+ blockbuster pill in ATTR-CM heart disorder (a pot'l $20B TAM)" - doc suggest add'l ⬆️side if Attruby real-world efficacy proves differentiated over tafamidis. $PFE $ALNY Citi reiterated $BBIO Buy-$67 after BridgeBio held an educational webinar to discuss pipeline drug BBP-418 and limb-girdle muscular dystrophy type 21/R9 (LGMD21/R9). Jefferies and Citi said in their research reports:
0 · Reply